接受阿扎那韦治疗的个体的病毒学失败及后续耐药情况。

Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.

作者信息

Stebbing Justin, Nathan Bif, Jones Rachael, McKenna Alex, Powles Tom, Bower Mark, Holmes Paul, Gazzard Brian, Nelson Mark

机构信息

Department of HIV Medicine, The Chelsea and Westminster Hospital, Imperial College School of Science, Technology and Medicine, London, UK.

出版信息

AIDS. 2007 Aug 20;21(13):1826-8. doi: 10.1097/QAD.0b013e3282742000.

DOI:10.1097/QAD.0b013e3282742000

PMID:17690587

Abstract

Few data exist regarding the resistance profile in individuals receiving atazanavir. We found that ritonavir-boosted atazanavir is not associated with the development of primary genotypic resistance in individuals failing this combination, without previous protease inhibitor failure. It is rarely associated with the acquisition of primary mutations in individuals with previous protease inhibitor exposure. This is particularly important because of the increasing use of atazanavir monotherapy, and implies that treatment failure is caused by lack of potency.

摘要

关于接受阿扎那韦治疗的个体的耐药情况，现有数据很少。我们发现，在未经历过蛋白酶抑制剂治疗失败的情况下，对于使用利托那韦增强的阿扎那韦治疗失败的个体，其原发性基因型耐药的发生与该治疗方案无关。在先前接触过蛋白酶抑制剂的个体中，该治疗方案很少与原发性突变的获得相关。鉴于阿扎那韦单药治疗的使用日益增加，这一点尤为重要，这意味着治疗失败是由效力不足导致的。